Worse clinical outcomes to PD-1 inhibitors plus chemotherapy were observed in patients with low PD-L1-expressing G/GEJ adenocarcinoma compared with PD-L1 CPS ≥ 5 cohort. Here, CD274 is linked to adenocarcinoma.